Skip to main content
. Author manuscript; available in PMC: 2022 Aug 5.
Published in final edited form as: Cell. 2021 Jul 22;184(16):4299–4314.e12. doi: 10.1016/j.cell.2021.06.031

Figure 2. Reactivation of CaMKII protects RGCs from excitotoxic and optic nerve injuries.

Figure 2.

(A-D) Confocal images of retinal whole-mounts showing surviving RGCs labeled by Tuj1 immunoreactivity at 7 days after NMDA injection in control (AAV-EBFP), or AAV-CaMKIIα WT, AAV-CaMKIIα K42R, and AAV-CaMKIIα T286D treated eyes. Scale bar, 40 µm.

(E) Quantification of RGC survival after treatment with CaMKIIα variants at 7 days post NMDA injection, expressed as numbers of RGCs (left Y-axis), and percentages of RGCs relative to those in the uninjured retina (right Y-axis). Data are presented as mean ± s.d., n=5 retinas per group. One-way ANOVA with Tukey’s multiple comparisons test, F:515.5, R2:0.9898, *P<0.0001.

(F-I) Confocal images of retinal whole-mounts showing surviving RGCs labeled by Tuj1 immunoreactivity at 7 days after NMDA injection in control (AAV-EBFP), or AAV-CaMKIIβ WT, AAV-CaMKIIβ K43R, and AAV-CaMKIIβ T287D treated eyes. Scale bar, 40 µm.

(J) Quantification of RGC survival after treatment with CaMKIIβ variants at 7 days post NMDA injection. Data are presented as mean ± s.d., n=5 retinas per group. One-way ANOVA with Tukey’s multiple comparisons test, F:423.3, R2:0.9876, *P<0.0001.

(K-N) Confocal images of retinal whole-mounts showing surviving RGCs labeled by Tuj1 immunoreactivity at 2 weeks after optic nerve crush in control (AAV-EBFP), or AAV-CaMKIIα WT, AAV-CaMKIIα K42R, and AAV-CaMKIIα T286D treated eyes. Scale bar, 40 µm.

(O) Quantification of RGC survival after treatment with CaMKIIα variants at 2 weeks post optic nerve crush. Data are presented as mean ± s.d., n=5 retinas per group. One-way ANOVA with Tukey’s multiple comparisons test, F:379.0, R2:0.9861, *P<0.0001.

(P-S) Confocal images of retinal whole-mounts showing surviving RGCs labeled by Tuj1 immunoreactivity at 2 weeks after optic nerve crush in control (AAV-EBFP), or AAV-CaMKIIβ WT, AAV-CaMKIIβ K43R, and AAV-CaMKIIβ T287D treated eyes. Scale bar, 40 µm.

(T) Quantification of RGC survival after treatment with CaMKIIβ variants at 2 weeks post optic nerve crush. Data are presented as mean ± s.d., n=5 retinas per group. One-way ANOVA with Tukey’s multiple comparisons test, F:361.3, R2:0.9855, *P<0.0001.

See also Figures S2 and S3.